Literature DB >> 9117143

Statins: within-group comparisons, statin escape and combination therapy.

M J Tikkanen1.   

Abstract

The successful use of statins in major coronary prevention trials has resulted in an explosive widening of their use. In most instances, statin therapy will result in adequate and sustained lowering of lipids. Comparing equal-weight doses, simvastatin is twice as effective as pravastatin and lovastatin in LDL-cholesterol lowering, and all three are more effective than fluvastatin according to recent comparative studies. Statin monotherapy is not always effective in severe hypercholesterolemia or in mixed (combined) hyperlipidemia with marked triglyceride elevations. All statins accepted for therapeutic use can be combined with resin or fibrate. Myopathy resulting from statin-fibrate combinations is less frequent than had been thought on the basis of early reports, and these combinations can be used in long-term therapy of mixed hyperlipidemia.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9117143     DOI: 10.1097/00041433-199612000-00008

Source DB:  PubMed          Journal:  Curr Opin Lipidol        ISSN: 0957-9672            Impact factor:   4.776


  5 in total

1.  Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin.

Authors:  Teddy Kosoglou; Ingo Meyer; Enrico P Veltri; Paul Statkevich; Bo Yang; Yali Zhu; Lillian Mellars; Stephen E Maxwell; James E Patrick; David L Cutler; Vijay K Batra; Melton B Affrime
Journal:  Br J Clin Pharmacol       Date:  2002-09       Impact factor: 4.335

Review 2.  Clinical positioning of HMG-CoA reductase inhibitors in lipid management protocols.

Authors:  M Cziraky
Journal:  Pharmacoeconomics       Date:  1998       Impact factor: 4.981

3.  Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.

Authors:  Hetal D Shah; Keyur H Parikh; Milan C Chag; Urmil G Shah; Hemang A Baxi; Anish H Chandarana; Ajay M Naik; Joyal N Shah; Sangeeta Iyer; Kanan J Shah; Ramesh K Goyal
Journal:  Exp Clin Cardiol       Date:  2007

4.  Cholesterol-lowering properties of Ganoderma lucidum in vitro, ex vivo, and in hamsters and minipigs.

Authors:  A Berger; D Rein; E Kratky; I Monnard; H Hajjaj; I Meirim; C Piguet-Welsch; J Hauser; K Mace; P Niederberger
Journal:  Lipids Health Dis       Date:  2004-02-18       Impact factor: 3.876

5.  Pharmacokinetic interactions and tolerability of rosuvastatin and ezetimibe: an open-label, randomized, multiple-dose, crossover study in healthy male volunteers.

Authors:  Hyungsub Kim; Hee Youn Choi; Yo-Han Kim; Kyun-Seop Bae; Jina Jung; Hankil Son; Hyeong-Seok Lim
Journal:  Drug Des Devel Ther       Date:  2018-04-11       Impact factor: 4.162

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.